恒瑞医药(600276.SH)：HRS-4642注射液纳入突破性治疗品种名单目前国内外尚无同类药物获批上市

智通财经02-06

智通财经APP讯，恒瑞医药(600276.SH)公告，近日，公司的HRS-4642注射液被国家药品监督管理局药品审评中心(“药审中心”)纳入突破性治疗品种名单。拟定适应症(或功能主治)：本品联合吉西他滨和紫杉醇(白蛋白结合型)用于携带KRAS G12D突变的晚期或转移性胰腺癌的一线治疗。据悉，胰腺癌是一种常见的消化道恶性肿瘤。最新全球癌症统计数据显示，2022年全球胰腺癌新发病例为510,566例...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2609420569?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-06 17:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609420569","market":"fut","top_or_hot":-1,"title":"恒瑞医药(600276.SH)：HRS-4642注射液纳入突破性治疗品种名单 目前国内外尚无同类药物获批上市","media":"智通财经","content":"<div>\n<p>智通财经APP讯，恒瑞医药(600276.SH)公告，近日，公司的HRS-4642注射液被国家药品监督管理局药品审评中心(“药审中心”)纳入突破性治疗品种名单。拟定适应症(或功能主治)：本品联合吉西他滨和紫杉醇(白蛋白结合型)用于携带KRAS G12D突变的晚期或转移性胰腺癌的一线治疗。据悉，胰腺癌是一种常见的消化道恶性肿瘤。最新全球癌症统计数据显示，2022年全球胰腺癌新发病例为510,566例...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1402598.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药(600276.SH)：HRS-4642注射液纳入突破性治疗品种名单 目前国内外尚无同类药物获批上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药(600276.SH)：HRS-4642注射液纳入突破性治疗品种名单 目前国内外尚无同类药物获批上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-06 17:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1402598.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，恒瑞医药(600276.SH)公告，近日，公司的HRS-4642注射液被国家药品监督管理局药品审评中心(“药审中心”)纳入突破性治疗品种名单。拟定适应症(或功能主治)：本品联合吉西他滨和紫杉醇(白蛋白结合型)用于携带KRAS G12D突变的晚期或转移性胰腺癌的一线治疗。据悉，胰腺癌是一种常见的消化道恶性肿瘤。最新全球癌症统计数据显示，2022年全球胰腺癌新发病例为510,566例...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1402598.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2495084118.USD","symbol_name":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1402598.html","article_id":"2609420569","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609420569","pubTimestamp":1770371265,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，恒瑞医药 公告，近日，公司的HRS-4642注射液被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。据悉，胰腺癌是一种常见的消化道恶性肿瘤。最新全球癌症统计数据显示，2022年全球胰腺癌新发病例为510,566例，居恶性肿瘤发病第12位;死亡病例为467,005例，居恶性肿瘤发病第6位，约占全球癌症死亡人数的5%。HRS-4642注射液是公司自主研发的KRAS G12D抑制剂，为脂质体剂型。经查询，目前国内外尚无同类药物获批上市。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK0188":"融资融券","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK0012":"证金概念","BK1191":"制药","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0028":"国家队","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU0359201612.USD":"贝莱德中国基金A2","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","BK0239":"医药制造","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0196":"行业龙头","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","BK0060":"抗癌","BK0183":"MSCI概念","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","01276":"恒瑞医药","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC"},"translate_title":"Hengrui Medicine (600276. SH): HRS-4642 injection is included in the list of breakthrough therapeutic varieties. At present, no similar drug has been approved for marketing at home and abroad","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.5,"01276":1.5},"content_text":"智通财经APP讯，恒瑞医药(600276.SH)公告，近日，公司的HRS-4642注射液被国家药品监督管理局药品审评中心(“药审中心”)纳入突破性治疗品种名单。拟定适应症(或功能主治)：本品联合吉西他滨和紫杉醇(白蛋白结合型)用于携带KRAS G12D突变的晚期或转移性胰腺癌的一线治疗。据悉，胰腺癌是一种常见的消化道恶性肿瘤。最新全球癌症统计数据显示，2022年全球胰腺癌新发病例为510,566例，居恶性肿瘤发病第12位;死亡病例为467,005例，居恶性肿瘤发病第6位，约占全球癌症死亡人数的5%。HRS-4642注射液是公司自主研发的KRAS G12D抑制剂，为脂质体剂型。该产品能特异性结合KRAS G12D，抑制MEK、ERK蛋白的磷酸化，发挥抗肿瘤作用。经查询，目前国内外尚无同类药物获批上市。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609420569","isCrawlerRequest":true}

恒瑞医药(600276.SH)：HRS-4642注射液纳入突破性治疗品种名单 目前国内外尚无同类药物获批上市

精彩评论

恒瑞医药(600276.SH)：HRS-4642注射液纳入突破性治疗品种名单目前国内外尚无同类药物获批上市